Related Experiment Video
Updated: Aug 31, 2026

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
Published on: February 9, 2016
Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine
A E Corey1, G M Rose, J D Conklin
1Biopharmaceutics Section, Norwich Eaton Pharmaceuticals, Inc., New York 13815.
Abstract:
The bioavailibity of mesalamine from enteric-coated mesalamine and sulphasalazine was determined following a single dose and at steady state in healthy subjects in crossover studies. Plasma concentrations and urinary excretion of mesalamine and its major metabolite, N-acetyl-5-aminosalicylic acid, were measured. After a single dose of enteric-coated mesalamine, about 10 h elapsed before the onset of measurable plasma drug concentrations, probably representing gastro-intestinal transit prior to drug release near the ileocaecal junction. The elimination kinetics were similar for a single oral dose and steady state using enteric-coated mesalamine, but after both single and multiple administration of enteric-coated mesalamine only about 20% of the mesalamine given was absorbed, with about 80% estimated to remain for colon therapeutic activity. It is concluded that, despite different mechanisms of mesalamine release, enteric-coated mesalamine and sulphasalazine produced similar mesalamine absorption.
Related Concept Videos
Factors Influencing Bioavailability: First-Pass Elimination
Drugs for Treatment of Ulcerative Colitis in IBD
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

